Ibex Medical Analytics

Ibex Medical Analytics is a pioneer in AI-based cancer diagnostics in pathology. The company's Galen™ platform utilizes artificial intelligence to develop clinical-grade algorithms and digital workflows that detect cancer as accurately as a human pathologist. In 2016, Ibex Medical Analytics was founded in Israel, and their latest achievement includes a $55.00M Series C investment on 06 September 2023 from notable investors such as Octopus Ventures, 83North, aMoon, Dell Capital, Planven Entrepreneur Ventures, and Sienna Investment Managers. The company addresses the increasing workloads of pathologists due to the rise in cancer prevalence and advances in personalized medicine. Ibex's Galen™ platform has demonstrated outstanding outcomes in clinical studies and contributes to the elimination of diagnostic errors, real-time quality control, reduced diagnosis time, and increased productivity for pathologists and providers. Deployed worldwide, Galen is the first-ever AI-powered cancer diagnostics platform used in routine clinical practice in pathology labs, with demonstrable success in improving the quality and efficiency of cancer diagnosis. Ibex Medical Analytics prides itself on being a multidisciplinary team of entrepreneurs, data scientists, software engineers, and medical experts, all working together to realize their vision of transforming cancer diagnosis with AI and improving patient care. If you are an outstanding professional passionate about making a real impact in the field, Ibex Medical Analytics welcomes individuals who are constantly seeking challenges and are team players.